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Dual antiplatelet therapy is the usual standard of care post-percutaneous coronary 
intervention (PCI)1. Nevertheless, in patients who are receiving concurrent systemic 
anticoagulation, there is a growing concern that the bleeding risk with the resulting 
triple antithrombotic therapy (TAT) may outweigh any potential benefits. This is 
further supported by the recognition that bleeding events post-PCI are associated with 
worse overall outcomes.2 Several studies have reported that the use of TAT results in 
similar rates of major adverse cardiovascular events (MACE) and major bleeding 
when compared to dual antithrombotic therapy (DAT)3–5. However, many of these 
studies are observational and underpowered to detect such events. As a result, the 
optimal antithrombotic regimen post-PCI remains a subject of debate. 
In the current issue of Journal of Cardiovascular Electrophysiology, Atti et al.6 report 
findings from their systematic review and meta-analysis of studies comparing TAT 
and DAT in anticoagulated patients undergoing PCI. The authors performed a 
comprehensive literature search to identify all relevant studies ever published: 15 
studies were eligible (5 randomised controlled trials (RCTs), 10 cohort studies) and 
included a total of 13,967 patients (7,349 TAT, 6,618 DAT). Meta-analysis using 
random-effects model demonstrated no difference in risk of trial defined MACE, all-
cause mortality and stroke but significantly lower rates of myocardial infarction (MI) 
and stent thrombosis with TAT. However, TAT was associated with significantly 
higher rates of trial defined major bleeding and Thrombolysis in Myocardial 
Infarction (TIMI) major bleeding but no difference in risk of intracranial bleeding. 
This article is protected by copyright. All rights reserved. 
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The findings from this meta-analysis are important and helps further our 
understanding of how to manage such challenging patients. Bleeding and thrombosis 
(ie. ischaemia) are often thought of as two distinct ends on the same spectrum. Using 
this principle, treatment that influences one should have the opposing effect on the 
other. However, the WOEST trial7 challenged this belief by demonstrating that the 
omission of aspirin from a TAT regimen reduced the risk of both thrombotic 
outcomes and bleeding, perhaps suggesting that not all clots are equal. An alternative 
explanation is that bleeding events from TAT may result in cessation of 
antithrombotic agents that promote subsequent MACE. It is perhaps superficial to 
simply consider the number of antithrombotic agents used per se in a particular 
treatment regimen, since many of these drugs have different mechanism of actions. 
Another limitation of using terminologies such as DAT and TAT is that it encourages 
the reader to assume that every DAT and TAT regime is identical when this is in fact 
far from the truth.  
Among patients with atrial fibrillation, the use of non-vitamin K antagonist oral 
anticoagulants (NOACs) has been associated with a reduced risk of major bleeding 
compared to warfarin, and have become the preferred option for thromboprophylaxis 
in patients with AF.8,9 There are a paucity of data on the use of NOACs in TAT 
regimes. As acknowledged by the authors, the majority of studies included patients on 
warfarin rather than NOACs. However, the three largest studies (PIONEER AF PCI10, 
REDUAL PCI11 and AUGUSTUS12; with a combined number of patients that 
exceeded all the remaining studies) included patients on NOACs in their DAT arm. 
The agent of choice for oral anticoagulation (OAC) in the TAT arms for both 
PIONEER AF PCI10 and REDUAL PCI11 was warfarin. As a result, these studies 
were largely comparing the outcomes of DAT (with a NOAC) and TAT (with 
This article is protected by copyright. All rights reserved. 
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warfarin). Therefore, the inclusion of these studies may have resulted in bias and 
inflated the risk of major bleeding with TAT. 
Interestingly, neither the subgroup analysis of RCTs or cohort studies showed any 
difference in rates of MI or stent thrombosis, although lower rates were seen with 
TAT in the pooled analysis of all studies. Indeed, there was a numerical trend for 
more stent thrombosis and the composite ischaemic outcome in placebo-treated 
patients compared to aspirin, in the AUGUSTUS trial. 
A few limitations to the study by Atti et al.6 ought to be highlighted. First, it is 
important to consider the effects of selection bias of the individual trials, many of 
which are observational in nature, on the overall meta-analysis. The individual 
treatments were likely to have been influenced by clinicians after weighing up the risk 
of ischaemia versus bleeding. It may therefore be assumed that patients who given 
TAT were deemed to have high ischaemic risk and those given DAT were deemed to 
have high bleeding risk. Second, there are significant variations in the duration of 
TAT used in the individual studies. Third, the studies were published between 2007 
and 2019. There are important advancements during this time from types of stents 
used to changes in medication regimens that may have influenced the outcomes. The 
significant changes over the past decade in favour of TAT and DAT are summarised 
in Table 1. Fourth, there is a lack of consistency between studies in the type of 
antiplatelets and anticoagulation agents used in DAT and TAT regimens. 
In summary, the important study by Atti et al.6 suggests that the use of TAT post-PCI 
may be associated with lower rates of MI and stent thrombosis but with increased risk 
of major bleeding. However, inter- and intra-group differences between those treated 
with DAT and TAT precludes drawing any strong conclusions from this meta-
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
 
analysis. For now, when choosing an OAC strategy in combination with one or more 
antiplatelets, a NOAC based strategy is likely to be safer compared to a warfarin 
based one.  
What about the need for aspirin? For many patients, an OAC plus P2Y12 inhibitor 
based DAT strategy may be an option, although in patients at high risk of stent 
thrombosis or ischaemic outcomes, a short period of aspirin may still be warranted as 
part of a TAT regimen. Indeed, the use of the different treatment regimens should 
ultimately be guided by detailed risk profile assessment of each individual.  
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Table 1: Changes over the past decade: 
Favouring TAT Favouring DAT 
Use of NOACs, which are associated with 
lower bleeding risk 
Improved stents used in PCI 
Better monitoring with warfarin More potent antiplatelets 
Increased use of PPIs  
Increased use of radial access for PCI  
TAT, triple antithrombotic therapy; DAT, dual antithrombotic 
therapy; PPI, proton pump inhibitors 
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